- Source type
- Article
- Access type
- Publisher
- Publisher
- The Wall Street Journal
- Date
- 2026-07-07
- Added
- 2026-07-09
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
60
General published source
- Publisher type
- General media
- Bias profile
- Elevated
This source is strongest for consumer context and regulatory status and weaker for safety and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 54/100
- Weak Support
- Clinical outcomes
- 54/100
- Weak Support
- Mechanism
- 54/100
- Weak Support
- Safety
- 54/100
- Weak Support
- Consumer context
- 67/100
- Context Source
- Trial discovery
- 54/100
- Weak Support
Best used for
- Context
- Public narrative
Weak for
- Clinical claims
- Safety conclusions
- Regulatory status
Used in Viral Vitalism
FDA Approved a New Immune-Targeting Drug for a Kidney Disease That Can Lead to Dialysis
Roles: Background
Show section-level references
- FDA approved Trutakna for IgA nephropathy under accelerated approval based on reduced proteinuria. It is a disease-marker approval, not yet proof that the drug prevents kidney failure or dialysis long term.Market/news corroboration; do not use as primary clinical source.
Related studies
No structured study record is currently attached to this source.
Related sources
California Board of Pharmacy recall subscriber alerts
Canonical source record for the republished rapid brief amgen-corlanor-sensipar-foreign-matter-recall.
- Trust score
- 91
- Publisher
- California Board of Pharmacy recall subscriber alerts
- Access
- Official
- Usage
- 1 connection
FDA drug recall database
Canonical source record for the republished rapid brief amgen-corlanor-sensipar-foreign-matter-recall.
- Trust score
- 94
- Publisher
- FDA drug recall database
- Access
- Official
- Usage
- 1 connection
Reuters: U.S. FDA approves Vera kidney disease drug
Independent FDA-approval reporting; add FDA label or company release before publishing.
- Trust score
- 60
- Publisher
- Reuters
- Access
- Publisher
- Usage
- 1 connection
Larimar Therapeutics: rolling BLA submission and open-label nomlabofusp data
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 60
- Publisher
- Larimar Therapeutics
- Access
- Publisher
- Usage
- 1 connection
People: 900,000 bottles of heart and kidney medications recalled
Canonical source record for the republished rapid brief amgen-corlanor-sensipar-foreign-matter-recall.
- Trust score
- 60
- Publisher
- People
- Access
- Publisher
- Usage
- 1 connection
Friedreich's Ataxia Research Alliance: nomlabofusp BLA and open-label update
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 82
- Publisher
- Friedreich's Ataxia Research Alliance
- Access
- Publisher
- Usage
- 1 connection